Literature DB >> 24366883

CRR9/CLPTM1L regulates cell survival signaling and is required for Ras transformation and lung tumorigenesis.

Michael A James1, Haris G Vikis, Everett Tate, Amy L Rymaszewski, Ming You.   

Abstract

The transmembrane protein CLPTM1L is overexpressed in non-small cell lung cancer, where it protects tumor cells from genotoxic apoptosis. Here, we show that RNA interference-mediated blockade of CLPTM1L inhibits K-Ras-induced lung tumorigenesis. CLPTM1L expression was required in vitro for morphologic transformation by H-RasV12 or K-RasV12, anchorage-independent growth, and survival of anoikis of lung tumor cells. Mechanistic investigations indicated that CLPTM1L interacts with phosphoinositide 3-kinase and is essential for Ras-induced AKT phosphorylation. Furthermore that the anti-apoptotic protein Bcl-xL is regulated by CLPTM1L independently of AKT activation. Constitutive activation of AKT or Bcl-xL rescued the transformed phenotype in CLPTM1L-depleted cells. The CLPTM1L gene lies within a cancer susceptibility locus at chromosome 5p15.33 defined by genome-wide association studies. The risk genotype at the CLPTM1L locus was associated with high expression of CLPTM1L in normal lung tissue, suggesting that cis-regulation of CLPTM1L may contribute to lung cancer risk. Taken together, our results establish a protumorigenic role for CLPTM1L that is critical for Ras-driven lung cancers, with potential implications for therapy and chemosensitization. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24366883      PMCID: PMC6005686          DOI: 10.1158/0008-5472.CAN-13-1617

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Detachment-mediated resistance to TRAIL-induced apoptosis is associated with stimulation of the PI3K/Akt pathway in fetal and adenocarcinoma epithelial colon cells.

Authors:  Lenka Kočí; Martina Hýžd'alová; Alena Vaculová; Jiřina Hofmanová; Alois Kozubík
Journal:  Cytokine       Date:  2011-04-08       Impact factor: 3.861

2.  PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy.

Authors:  Lindsey D Mayo; Jack E Dixon; Donald L Durden; Nickolas K Tonks; David B Donner
Journal:  J Biol Chem       Date:  2001-11-29       Impact factor: 5.157

3.  Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.

Authors:  Kian-Huat Lim; Christopher M Counter
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

4.  Homozygous codeletion and differential decreased expression of p15INK4b, p16INK4a-alpha and p16INK4a-beta in mouse lung tumor cells.

Authors:  C R Herzog; E V Soloff; A L McDoniels; F L Tyson; A M Malkinson; A Haugen-Strano; R W Wiseman; M W Anderson; M You
Journal:  Oncogene       Date:  1996-11-07       Impact factor: 9.867

5.  Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells.

Authors:  Xiaoyong Lei; Zexiang Huang; Miao Zhong; Bingyang Zhu; Shengsong Tang; Duanfang Liao
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2007-05       Impact factor: 3.848

Review 6.  The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

Authors:  Lindsey D Mayo; David B Donner
Journal:  Trends Biochem Sci       Date:  2002-09       Impact factor: 13.807

7.  A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33.

Authors:  Gloria M Petersen; Laufey Amundadottir; Charles S Fuchs; Peter Kraft; Rachael Z Stolzenberg-Solomon; Kevin B Jacobs; Alan A Arslan; H Bas Bueno-de-Mesquita; Steven Gallinger; Myron Gross; Kathy Helzlsouer; Elizabeth A Holly; Eric J Jacobs; Alison P Klein; Andrea LaCroix; Donghui Li; Margaret T Mandelson; Sara H Olson; Harvey A Risch; Wei Zheng; Demetrius Albanes; William R Bamlet; Christine D Berg; Marie-Christine Boutron-Ruault; Julie E Buring; Paige M Bracci; Federico Canzian; Sandra Clipp; Michelle Cotterchio; Mariza de Andrade; Eric J Duell; J Michael Gaziano; Edward L Giovannucci; Michael Goggins; Göran Hallmans; Susan E Hankinson; Manal Hassan; Barbara Howard; David J Hunter; Amy Hutchinson; Mazda Jenab; Rudolf Kaaks; Charles Kooperberg; Vittorio Krogh; Robert C Kurtz; Shannon M Lynch; Robert R McWilliams; Julie B Mendelsohn; Dominique S Michaud; Hemang Parikh; Alpa V Patel; Petra H M Peeters; Aleksandar Rajkovic; Elio Riboli; Laudina Rodriguez; Daniela Seminara; Xiao-Ou Shu; Gilles Thomas; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Stephen K Van Den Eeden; Jarmo Virtamo; Jean Wactawski-Wende; Zhaoming Wang; Brian M Wolpin; Herbert Yu; Kai Yu; Anne Zeleniuch-Jacquotte; Joseph F Fraumeni; Robert N Hoover; Patricia Hartge; Stephen J Chanock
Journal:  Nat Genet       Date:  2010-01-24       Impact factor: 38.330

8.  Common 5p15.33 and 6p21.33 variants influence lung cancer risk.

Authors:  Yufei Wang; Peter Broderick; Emily Webb; Xifeng Wu; Jayaram Vijayakrishnan; Athena Matakidou; Mobshra Qureshi; Qiong Dong; Xiangjun Gu; Wei Vivien Chen; Margaret R Spitz; Timothy Eisen; Christopher I Amos; Richard S Houlston
Journal:  Nat Genet       Date:  2008-11-02       Impact factor: 38.330

9.  Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.

Authors:  Michael A James; Weidong Wen; Yian Wang; Lauren A Byers; John V Heymach; Kevin R Coombes; Luc Girard; John Minna; Ming You
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

10.  CLPTM1L is overexpressed in lung cancer and associated with apoptosis.

Authors:  Zhenhua Ni; Kun Tao; Guo Chen; Qingge Chen; Jianmin Tang; Xuming Luo; Peihao Yin; Jihong Tang; Xiongbiao Wang
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more
  29 in total

1.  Fine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci.

Authors:  Linda Kachuri; Christopher I Amos; James D McKay; Mattias Johansson; Paolo Vineis; H Bas Bueno-de-Mesquita; Marie-Christine Boutron-Ruault; Mikael Johansson; J Ramón Quirós; Sabina Sieri; Ruth C Travis; Elisabete Weiderpass; Loic Le Marchand; Brian E Henderson; Lynne Wilkens; Gary E Goodman; Chu Chen; Jennifer A Doherty; David C Christiani; Yongyue Wei; Li Su; Shelley Tworoger; Xuehong Zhang; Peter Kraft; David Zaridze; John K Field; Michael W Marcus; Michael P A Davies; Russell Hyde; Neil E Caporaso; Maria Teresa Landi; Gianluca Severi; Graham G Giles; Geoffrey Liu; John R McLaughlin; Yafang Li; Xiangjun Xiao; Gord Fehringer; Xuchen Zong; Robert E Denroche; Philip C Zuzarte; John D McPherson; Paul Brennan; Rayjean J Hung
Journal:  Carcinogenesis       Date:  2015-11-20       Impact factor: 4.944

Review 2.  Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.

Authors:  Karima Ait-Aissa; Johnathan D Ebben; Andrew O Kadlec; Andreas M Beyer
Journal:  Pharmacol Res       Date:  2016-07-06       Impact factor: 7.658

Review 3.  Inherited pancreatic cancer.

Authors:  Fei Chen; Nicholas J Roberts; Alison P Klein
Journal:  Chin Clin Oncol       Date:  2017-12

4.  The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.

Authors:  Z Chen; J Wang; Y Bai; S Wang; X Yin; J Xiang; X Li; M He; X Zhang; T Wu; P Xu; H Guo
Journal:  Cancer Gene Ther       Date:  2016-12-16       Impact factor: 5.987

5.  CLPTM1L gene rs402710 (C > T) and rs401681 (C > T) polymorphisms associate with decreased cancer risk: a meta-analysis.

Authors:  Jianzhou Tang; Changming Hu; Hua Mei; Liang Peng; Hui Li
Journal:  Oncotarget       Date:  2017-11-01

6.  Association between CLPTM1L-TERT rs401681 polymorphism and pancreatic cancer risk among Chinese Han population.

Authors:  Chengli Liu; Yingjie Wang; Hui Huang; Cheng Wang; Hui Zhang; Yalin Kong; Hongyi Zhang
Journal:  Tumour Biol       Date:  2014-02-28

7.  Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling.

Authors:  László G Puskás; Imola Mán; Gabor Szebeni; László Tiszlavicz; Susan Tsai; Michael A James
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

8.  Cleft lip and palate transmembrane protein 1 rs31489 polymorphism is associated with lung cancer risk: a meta-analysis.

Authors:  Yuansheng Zang; Wei Nie; Zheng Fang; Bing Li
Journal:  Tumour Biol       Date:  2014-02-18

9.  A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer.

Authors:  Jun Zhong; Ashley Jermusyk; Lang Wu; Jason W Hoskins; Irene Collins; Evelina Mocci; Mingfeng Zhang; Lei Song; Charles C Chung; Tongwu Zhang; Wenming Xiao; Demetrius Albanes; Gabriella Andreotti; Alan A Arslan; Ana Babic; William R Bamlet; Laura Beane-Freeman; Sonja Berndt; Ayelet Borgida; Paige M Bracci; Lauren Brais; Paul Brennan; Bas Bueno-de-Mesquita; Julie Buring; Federico Canzian; Erica J Childs; Michelle Cotterchio; Mengmeng Du; Eric J Duell; Charles Fuchs; Steven Gallinger; J Michael Gaziano; Graham G Giles; Edward Giovannucci; Michael Goggins; Gary E Goodman; Phyllis J Goodman; Christopher Haiman; Patricia Hartge; Manal Hasan; Kathy J Helzlsouer; Elizabeth A Holly; Eric A Klein; Manolis Kogevinas; Robert J Kurtz; Loic LeMarchand; Núria Malats; Satu Männistö; Roger Milne; Rachel E Neale; Kimmie Ng; Ofure Obazee; Ann L Oberg; Irene Orlow; Alpa V Patel; Ulrike Peters; Miquel Porta; Nathaniel Rothman; Ghislaine Scelo; Howard D Sesso; Gianluca Severi; Sabina Sieri; Debra Silverman; Malin Sund; Anne Tjønneland; Mark D Thornquist; Geoffrey S Tobias; Antonia Trichopoulou; Stephen K Van Den Eeden; Kala Visvanathan; Jean Wactawski-Wende; Nicolas Wentzensen; Emily White; Herbert Yu; Chen Yuan; Anne Zeleniuch-Jacquotte; Robert Hoover; Kevin Brown; Charles Kooperberg; Harvey A Risch; Eric J Jacobs; Donghui Li; Kai Yu; Xiao-Ou Shu; Stephen J Chanock; Brian M Wolpin; Rachael Z Stolzenberg-Solomon; Nilanjan Chatterjee; Alison P Klein; Jill P Smith; Peter Kraft; Jianxin Shi; Gloria M Petersen; Wei Zheng; Laufey T Amundadottir
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

Review 10.  A Decade of GWAS Results in Lung Cancer.

Authors:  Yohan Bossé; Christopher I Amos
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-06-14       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.